Our Philadelphia breast implant cancer lawyers are evaluating cases involving women who developed anaplastic large cell lymphoma (ALCL) after receiving breast implants. Breast implant-associated ALCL is a form of non-Hodgkin’s lymphoma that develops in the seroma fluid between implants and scar-tissue capsules that grow around implants after surgery.

This deadly cancer may also be abbreviated BIA-ALCL (breast implant associated anaplastic large cell lymphoma). BIA-ALCL is a blood cancer rather than a cancer of the breast and can take up to 10 years to develop.

Breast Implants that Cause Lymphoma (ALCL)

Breast implants associated with an increased risk of ALCL include saline and silicone gel implants and those with smooth and textured surfaces.

Silicone vs. Saline Implants

Most cases of BIA-ALCL appeared with silicone gel implants. The FDA restricted silicone implants between 1992 and 2006 and lifted the restriction in 2006. Though silicone implants were sold for a much shorter time than saline implants, even more cases of ALCL were found in patients with silicone implants.

Textured vs. Smooth Implants

Implants with textured as opposed to smooth surfaces pose the greater risk of ALCL development. As noted below, the risk for patients with textured implants is 67.6 times greater than the risk for patients without implants.

Manufacturers of breast implants include:

  • Allergan, Inc.
  • Ideal Implant Inc.
  • Johnson & Johnson / Mentor Worldwide LLC
  • Sientra

Studies Showing Link between Breast Implants and ALCL

The increased risk of ALCL following breast implant surgery has been apparent for decades.

  • An association between ALCL and breast implants was noted as early as 1997 in the journal Plastic and Reconstructive Surgery.
  • The U.S. Food & Drug Administration (FDA) identified an association between ALCL and breast implants in 2011.
  • A study reported in the Journal of Clinical Oncology in 2014 described the clinical outcome for published cases of breast implant-associated ALCL between 1997 and December 2012.
  • In 2016, the World Health Organization (WHO) recognized the link between breast implants and ALCL.
  • As of February 2017, at least 359 medical device reports (MDRs) of breast cancer-associated ALCL have been received by the FDA. These reports include at least 9 deaths.
  • In March 2017, the FDA acknowledged that it agrees with the World Health Organization’s designation of ALCL as a rare T-cell lymphoma that can develop in a patient with breast implants.
  • A study reported in the May 2017 issue of Plastic and Reconstructive Surgery, which considered documented cases of BIA-ALCL from 1996 to 2015, showed that patients who received textured breast implants were 67.6 times more likely to develop ALCL than patients without breast implants.

philadelphia breast implant cancer lawyersBreast Implant Cancer Lawsuits

Lawsuits brought by Philadelphia breast implant cancer lawyers may allege that implant manufacturers:

  • designed and manufactured defective and unreasonably dangerous medical devices
  • knew or should have known of the increased risk of developing ALCL after breast implant surgery
  • failed to adequately warn physicians and consumers of the increased risk of ALCL with breast implants

Contact our Philadelphia Breast Implant Cancer Lawyers

If you developed ALCL after breast implant surgery, one of Feldman & Pinto’s Philadelphia breast implant cancer lawyers can help you obtain justice from the responsible parties. Please contact us, today, for a free evaluation of your breast implant lymphoma case.